Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook

Horizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.70, $0.30 better than the analyst estimate of $0.40. Revenue for the quarter came in at $292.7 million versus the consensus estimate of $185.7 million.

Horizon Pharma sees FY2015 revenue of $750-760 million, versus prior guidance of $660-680 million and the consensus of $683.3 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings